

**MTN 037 - A Phase 1 Safety and Pharmacokinetic Study of PC-1005 (MIV-150/Zinc Acetate/Carrageenan Gel)
Administered Rectally to HIV-1 Seronegative Adults
Data as of December 5, 2022**

Visit Adherence: Completion of Procedures During Enrollment and Follow-up¹ by Site

	Pittsburgh	Birmingham	All Sites
Participants Enrolled	6	7	13
1. Behavioral Assessment Required and Expected	24	26	50
Completed	24 (100.0%)	26 (100.0%)	50 (100.0%)
2. In-depth Interview Required and Expected	6	5	11
Completed	6 (100.0%)	5 (100.0%)	11 (100.0%)
3. General/Targeted Physical Exams Required and Expected	12	14	26
Completed	12 (100.0%)	14 (100.0%)	26 (100.0%)
4. Rectal Exam Required and Expected	54	57	111
Completed	54 (100.0%)	57 (100.0%)	111 (100.0%)
5. NAAT (Pharyngeal) for GC/CT Required and Expected	6	7	13
Completed	6 (100.0%)	7 (100.0%)	13 (100.0%)
6. NAAT (Urine) for GC/CT Required and Expected	6	7	13
Completed	6 (100.0%)	7 (100.0%)	13 (100.0%)
7. NAAT (Pelvic) for GC/CT Required and Expected (Female Only)	3	3	6
Completed	3 (100.0%)	3 (100.0%)	6 (100.0%)
8. NAAT (Anorectal) for GC/CT Required and Expected	6	7	13
Completed	6 (100.0%)	7 (100.0%)	13 (100.0%)
9. Pregnancy Test Required and Expected (Female Only)	15	15	30
Completed	15 (100.0%)	15 (100.0%)	30 (100.0%)

¹ Protocol-required follow-up visit procedures are expected only once the visit window has closed, and only for participants who attend the visit. If a participant misses a visit, as documented by a Missed Visit eCRF, the procedures for that visit will not be included as expected.

**MTN 037 - A Phase 1 Safety and Pharmacokinetic Study of PC-1005 (MIV-150/Zinc Acetate/Carrageenan Gel)
Administered Rectally to HIV-1 Seronegative Adults
Data as of December 5, 2022**

Visit Adherence: Completion of Procedures During Enrollment and Follow-up¹ by Site

	Pittsburgh	Birmingham	All Sites
10. Hematology Required and Expected	24	25	49
Completed	24 (100.0%)	25 (100.0%)	49 (100.0%)
11. Differentials Required and Expected	24	25	49
Completed	24 (100.0%)	25 (100.0%)	49 (100.0%)
12. Blood Chemistries Required and Expected	42	44	86
Completed	42 (100.0%)	44 (100.0%)	86 (100.0%)
13. Plasma for Archive Required and Expected	6	7	13
Completed	6 (100.0%)	7 (100.0%)	13 (100.0%)
14. Plasma for PK Required and Expected	42	43	85
Completed	42 (100.0%)	43 (100.0%)	85 (100.0%)
15. Syphilis Serology Required and Expected	6	7	13
Completed	6 (100.0%)	7 (100.0%)	13 (100.0%)
16. HIV-1/2 Tests Required and Expected	18	19	37
Completed	18 (100.0%)	19 (100.0%)	37 (100.0%)
17. Vaginal Fluid for PK Required and Expected (Female Only)	12	12	24
Completed	12 (100.0%)	12 (100.0%)	24 (100.0%)
18. Anal Swab for HPV Required and Expected	24	25	49
Completed	24 (100.0%)	25 (100.0%)	49 (100.0%)

¹ Protocol-required follow-up visit procedures are expected only once the visit window has closed, and only for participants who attend the visit. If a participant misses a visit, as documented by a Missed Visit eCRF, the procedures for that visit will not be included as expected.

**MTN 037 - A Phase 1 Safety and Pharmacokinetic Study of PC-1005 (MIV-150/Zinc Acetate/Carrageenan Gel)
Administered Rectally to HIV-1 Seronegative Adults
Data as of December 5, 2022**

Visit Adherence: Completion of Procedures During Enrollment and Follow-up¹ by Site

	Pittsburgh	Birmingham	All Sites
19. Rectal Enema Effluent for PD Required and Expected	30	32	62
Completed	30 (100.0%)	32 (100.0%)	62 (100.0%)
20. Rectal Fluid for PD Required and Expected	30	32	62
Completed	30 (100.0%)	32 (100.0%)	62 (100.0%)
21. Rectal Fluid for PK Required and Expected	24	25	49
Completed	24 (100.0%)	25 (100.0%)	49 (100.0%)
22. Rectal Tissue for PD Required and Expected	30	32	62
Completed	30 (100.0%)	32 (100.0%)	62 (100.0%)
23. Rectal Tissue for Histology Required and Expected	30	32	62
Completed	30 (100.0%)	32 (100.0%)	62 (100.0%)
24. Rectal Tissue for Archive Required and Expected	30	32	62
Completed	30 (100.0%)	32 (100.0%)	62 (100.0%)
25. Rectal Tissue for PK Required and Expected	24	25	49
Completed	24 (100.0%)	25 (100.0%)	49 (100.0%)

¹ Protocol-required follow-up visit procedures are expected only once the visit window has closed, and only for participants who attend the visit. If a participant misses a visit, as documented by a Missed Visit eCRF, the procedures for that visit will not be included as expected.